Supplement and nutraceutical merchants are not automatically prohibited by card networks or mainstream payment processors. When people ask why payment processors decline supplement merchants, the answer is rarely the word “supplement” itself. Underwriters look at what a business sells, what it claims those products do, how it markets them, how it bills customers and how its refunds and disputes behave. That is why two brands selling similar capsules can receive very different underwriting outcomes. This guide separates the rules set by card networks, processors and regulators, and shows what a supplement business can review before it applies.
Supplement businesses are not automatically prohibited
Supplement businesses are not prohibited as a category: the card-network rules and mainstream processor policies reviewed for this guide restrict specific claims, unsafe products and deceptive billing, not dietary supplements as such.
The wording of the rules shows where the line sits:
- Visa. The Visa Core Rules (April 2026 edition) require acquirers to prevent card acceptance for “products that claim or imply a similar efficacy as prescription drugs, controlled substances, or recreational/street drugs, irrespective of claims of legality”. The test is the claim, not the product category.
- Stripe. Its restricted-businesses list (updated 22 September 2026) prohibits “pseudo-pharmaceuticals or nutraceuticals that are not safe or make harmful claims”. The word “supplement” does not appear on the page.
- Shopify Payments. Its eligibility rules prohibit “pharmaceuticals and other products that make health claims that are not verified by a local or national regulatory body”.
- PayPal. Its Acceptable Use Policy prohibits products “that present a risk to consumer safety”. Supplements are not named.
Visa’s Integrity Risk Program points the same way. It describes “high integrity risk” merchants as businesses “that are legal” but that need proper controls, and supplements are not listed in any of its tiers.
In practice, a processor assesses four separate things:
- The product category: what is in the catalogue.
- The claims: what the business says those products do.
- The marketing: how and where those claims are made.
- The billing model: how and when customers are charged.
A compliant vitamin store and a funnel selling a “miracle” weight-loss product share a category. They do not share a risk profile.
Product and health claims can change the underwriting decision
Health claims can materially change how a payment processor assesses a supplement merchant, because a claim can make an ordinary supplement look like an unapproved drug.
In the United States, the FDA does not approve dietary supplements or their structure/function claims before sale. Two kinds of claim need to be kept apart:
- Structure/function claims describe how a nutrient affects the normal structure or function of the body. The label must carry a disclaimer that the product “is not intended to diagnose, treat, cure or prevent any disease”, and the FDA must be notified within 30 days of marketing.
- Disease claims say a product treats, cures, mitigates or prevents a disease. Only a drug can lawfully make one, so a supplement marketed this way is treated as an unapproved new drug. In September 2021, the FDA and FTC jointly warned 10 companies selling supplements that claimed to treat diabetes.
The FTC adds a substantiation standard. Its Health Products Compliance Guidance (December 2022) expects health claims to rest on “competent and reliable scientific evidence”, generally randomised, controlled human trials.
The UK draws a similar line: the MHRA can classify a supplement presented for medicinal use as a medicine, and the CAP Code only allows health claims authorised on the GB Nutrition and Health Claims Register.
For underwriting, the practical point is consistency: a processor reads the label, product page and advertising together. A capsule described as supporting normal energy levels on the label but promoted as a cure in an advert has a different risk profile from the same capsule marketed consistently.
Free trials and negative-option billing create a different risk profile
Free trials and negative-option billing carry specific card-network rules, because unclear future charges are a direct route to customer disputes.
Not every supplement brand uses these models, and many sell one-off orders. But “free trial, then automatic rebilling” funnels have a history in the supplement market that networks and regulators remember.
Visa’s rules for negative-option merchants require clear disclosure of the terms on the checkout screen, express consent through a “click-to-accept” button, written notice at least 7 days before the next charge when a trial or introductory period is ending, and an easy online cancellation method. Visa also gives cardholders a dispute right where goods were bought through a trial or introductory offer and the cardholder “was not clearly advised of further Transactions”.
Visa’s Integrity Risk Program lists card-absent negative-option merchants under merchant category code 5968 as a higher-risk tier. That classification follows the billing model, not the product. On the Mastercard side, a 2019 J.P. Morgan merchant bulletin reported that Mastercard’s free-trial registration rules for physical products were introduced “with a primary focus on nutraceuticals”.
In the US, the Restore Online Shoppers’ Confidence Act (ROSCA) requires clear disclosure of material terms, express informed consent before charging and a simple way to stop recurring charges. As of October 2026, the FTC’s 2024 “click-to-cancel” rule is not in force, having been vacated in July 2025, but ROSCA enforcement continues.
The clearest example of why processors care is FTC v. Apex Capital, which concerned supplement and personal-care “free trial” offers that the FTC alleged were run through shell companies to obtain merchant accounts and evade chargeback monitoring. In January 2020, a payment processor accused of keeping those accounts open settled with the FTC for a $3.5 million judgment and restrictions on future processing. Processors carry enforcement risk for the merchants they accept.
Marketing practices can matter as much as the product
Marketing practices can create payment risk even when the product itself is ordinary, so underwriters often review a brand’s advertising and sales funnel alongside its catalogue.
Several rules reach marketing directly. Stripe prohibits businesses that “make outrageous claims, use deceptive testimonials, use high-pressure upselling or use fake testimonials”. The FTC’s health-claim guidance covers endorsements and testimonials, and the MHRA considers how a product is presented across websites, social media and customer reviews.
In practice, reviews commonly look at:
- landing pages, paid adverts and affiliate content, including any health claims;
- before-and-after imagery and testimonials;
- how clearly prices and any future charges are shown;
- refund promises, and whether the policy behind them matches;
- whether the advert, product page and checkout describe the same offer.
An ordinary multivitamin promoted through exaggerated affiliate pages can therefore look riskier to a processor than a specialist product marketed with care.
Refund history, disputes and fulfilment affect risk
Refund history, customer disputes and fulfilment performance show a processor how a supplement business behaves after the sale, which is why two similar brands can be assessed differently.
Chargebacks can be a symptom of underlying issues rather than the original cause: unclear claims, surprise charges and slow delivery can all lead to disputes, and card networks run monitoring programmes for merchants whose dispute and fraud levels become excessive. Where an acquirer terminates a merchant for one of the reasons listed in Mastercard’s MATCH rules, it must add the business to the MATCH list. A listing stays there for five years, so processing history can follow a business into future applications.
Underwriters commonly look at these operational signals:
- Refund behaviour: how often orders are refunded, and how promptly.
- Customer complaints: volume and recurring themes.
- Fulfilment: delivery times. Mastercard’s 2019 trial rules, as summarised by J.P. Morgan, start a trial when the customer receives the product.
- Billing descriptors: whether customers recognise the charge on their statement.
These checks are common industry practice rather than published network rules, and providers weigh them differently. For the dispute side, see our guide to reducing chargebacks in high-risk industries.
What underwriters typically review before approving a supplement merchant
Supplement merchant underwriting typically reviews the products, the claims made about them, the billing model and the business behind them.
This checklist reflects common industry practice; each provider sets its own requirements.
- Products sold: the full catalogue, including any ingredients that are restricted in the markets you sell to.
- Product and health claims: labels, product pages and adverts checked for disease or drug-like claims.
- Website and advertising: clear business identity, contact details, prices and policies, with affiliate content consistent with your own.
- Billing model: one-off purchases, or trials and automatic rebilling, with how terms and consent are shown.
- Refund and cancellation policy: visible, specific and followed in practice.
- Target markets: where customers are. Visa requires a transaction to be legal in both the cardholder’s and the merchant’s jurisdiction.
- Business structure and ownership: company registration, directors and beneficial owners (KYB).
- Fulfilment model: who ships, from where and how quickly.
- Processing history: previous statements, and any account closures, where available.
- Refund and dispute history: how past orders have resolved.
For a cross-vertical view, see what each high-risk vertical has to evidence. For the paperwork, see our application documents checklist.
High risk does not mean automatically declined
A higher-risk category can require more underwriting without being automatically rejected.
These terms are often used interchangeably, but they mean different things:
- Prohibited: the provider will not process the activity at all. Examples include unsafe products, or claims of prescription-drug-like efficacy under Visa’s rules.
- Restricted: the activity needs specific approval or additional conditions before processing.
- Enhanced review or “high risk”: a legal business that receives closer scrutiny because of its claims, billing model, markets or history.
- Case-by-case approval: each application is assessed on its own facts, not on the category label.
A decline from one provider is therefore not a verdict on the whole category. It usually reflects how that provider read a specific combination of products, claims and practices. The same logic applies to other scrutinised verticals, as our guide on why payment processors reject peptide merchants explains. If you are comparing providers, our article on payment gateway options for supplement brands covers what to look for.
How Niftipay reviews supplement and nutraceutical merchants
Niftipay reviews supplement and nutraceutical merchants individually, and approval is not guaranteed.
Niftipay Card Payments lists supplement and nutraceutical merchants among the businesses it can review, assessed on their products, marketing and refund history. The broader assessment can also cover target markets, business structure and compliance profile. Applications are normally reviewed within two to five business days. Complex business models or requests for additional documentation can take longer. To see the payment methods and integrations available, read how Niftipay handles payment processing for supplement brands.
As part of KYB, Niftipay asks for company details and the identity of beneficial owners holding 25% or more.
Niftipay Card Payments processes each payment as an individual transaction. It does not offer subscriptions, recurring billing or stored cards. Merchants whose model depends on automatic rebilling should take that into account before applying.
Supplement Merchant Underwriting FAQs
Are supplement businesses automatically considered high risk?
No. Supplement businesses are not prohibited as a category by the card-network rules and mainstream processor policies reviewed for this guide. Some claims, billing models and marketing practices lead to enhanced underwriting, so the risk assessment depends on the individual business rather than the word “supplement”.
Why do payment processors decline supplement merchants?
Declines usually trace back to disease or drug-like product claims, aggressive or inconsistent marketing, free-trial and automatic rebilling models, refund and dispute history, or an incomplete compliance profile such as unclear ownership. Each provider weighs these factors against its own policies.
Can supplement businesses accept card payments?
Yes. A supplement business can accept card payments where the provider has approved the business and its payment setup. Approval is not automatic: providers review the products, claims, marketing, billing model and history.
Do free trials make supplement payment processing harder?
Usually, yes. Free trials and negative-option billing are subject to additional card-network requirements, including clear disclosure, express consent, written notice at least 7 days before the next charge when a trial is ending, and easy cancellation. They are also linked to higher dispute exposure when future charges are unclear.
What does Niftipay review for supplement and nutraceutical merchants?
Niftipay reviews supplement and nutraceutical merchants individually, assessing their products, marketing and refund history alongside target markets, business structure and compliance profile. Approval is not guaranteed, and Niftipay Card Payments processes individual transactions rather than subscriptions.